Analysts Set Expectations for Ikena Oncology, Inc.’s Q1 2024 Earnings (NASDAQ:IKNA)

Ikena Oncology, Inc. (NASDAQ:IKNA – Get Rating) – Stock analysts at William Blair issued their Q1 2024 earnings per share estimates for Ikena Oncology in a research report issued to clients and investors on Tuesday, March 14th. William Blair analyst M. Phipps anticipates that the company will earn ($0.70) per share for the quarter. The consensus estimate for Ikena Oncology’s current full-year earnings is ($2.44) per share. William Blair also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.75) EPS, Q3 2024 earnings at ($0.78) EPS, Q4 2024 earnings at ($0.82) EPS and FY2027 earnings at ($5.24) EPS.

Other research analysts also recently issued research reports about the company. HC Wainwright reduced their price objective on Ikena Oncology from $26.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, November 29th. Credit Suisse Group reduced their price objective on Ikena Oncology from $16.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday.

Ikena Oncology Trading Up 1.2 %

Shares of Ikena Oncology stock opened at $4.30 on Thursday. The company has a market capitalization of $155.92 million, a P/E ratio of -2.97 and a beta of 0.80. The stock has a fifty day simple moving average of $3.91 and a 200 day simple moving average of $3.40. Ikena Oncology has a 12-month low of $1.94 and a 12-month high of $8.99.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its stake in shares of Ikena Oncology by 103.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,119 shares of the company’s stock worth $160,000 after acquiring an additional 13,255 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Ikena Oncology by 25.4% during the 1st quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock worth $104,000 after acquiring an additional 3,482 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of Ikena Oncology by 163.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 20,720 shares of the company’s stock worth $92,000 after acquiring an additional 12,854 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Ikena Oncology by 148.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 25,145 shares of the company’s stock worth $90,000 after acquiring an additional 15,013 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Ikena Oncology during the 2nd quarter worth $69,000. Institutional investors own 72.40% of the company’s stock.

About Ikena Oncology

(Get Rating)

Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.